KR20160022912A - 항-fcrh5 항체 - Google Patents

항-fcrh5 항체 Download PDF

Info

Publication number
KR20160022912A
KR20160022912A KR1020167001897A KR20167001897A KR20160022912A KR 20160022912 A KR20160022912 A KR 20160022912A KR 1020167001897 A KR1020167001897 A KR 1020167001897A KR 20167001897 A KR20167001897 A KR 20167001897A KR 20160022912 A KR20160022912 A KR 20160022912A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
antibody
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167001897A
Other languages
English (en)
Korean (ko)
Inventor
앨런 제이. 주니어 에벤스
메레디쓰 씨. 하젠
조-앤 홍고
제니퍼 더블유. 존스턴
티무 티. 준틸라
지 리
앤드류 쥐. 폴슨
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20160022912A publication Critical patent/KR20160022912A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A61K47/48384—
    • A61K47/48561—
    • A61K47/48676—
    • A61K47/48715—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167001897A 2013-06-24 2014-06-24 항-fcrh5 항체 Ceased KR20160022912A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838534P 2013-06-24 2013-06-24
US61/838,534 2013-06-24
PCT/US2014/043952 WO2014210064A1 (en) 2013-06-24 2014-06-24 Anti-fcrh5 antibodies

Publications (1)

Publication Number Publication Date
KR20160022912A true KR20160022912A (ko) 2016-03-02

Family

ID=51212984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167001897A Ceased KR20160022912A (ko) 2013-06-24 2014-06-24 항-fcrh5 항체

Country Status (29)

Country Link
US (3) US10435471B2 (OSRAM)
EP (3) EP3013861B1 (OSRAM)
JP (2) JP6684208B2 (OSRAM)
KR (1) KR20160022912A (OSRAM)
CN (2) CN105473618A (OSRAM)
AR (1) AR096687A1 (OSRAM)
AU (2) AU2014302617B2 (OSRAM)
BR (1) BR112015032224B1 (OSRAM)
CA (1) CA2915480C (OSRAM)
DK (3) DK3013861T3 (OSRAM)
ES (3) ES2659229T3 (OSRAM)
FI (1) FI3736291T3 (OSRAM)
HK (1) HK1222663A1 (OSRAM)
HR (3) HRP20180352T1 (OSRAM)
HU (3) HUE036581T2 (OSRAM)
IL (2) IL243129B (OSRAM)
LT (3) LT3013861T (OSRAM)
MX (1) MX376663B (OSRAM)
MY (2) MY176285A (OSRAM)
NO (1) NO2955475T3 (OSRAM)
PL (3) PL3013861T3 (OSRAM)
PT (3) PT3013861T (OSRAM)
RS (3) RS56878B1 (OSRAM)
RU (2) RU2687132C2 (OSRAM)
SG (2) SG10201804338PA (OSRAM)
SI (3) SI3013861T1 (OSRAM)
TW (1) TWI725931B (OSRAM)
WO (1) WO2014210064A1 (OSRAM)
ZA (2) ZA201509261B (OSRAM)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
EA201790569A1 (ru) 2014-09-12 2017-08-31 Дженентек, Инк. Антитела и иммуноконъюгаты против cll-1
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3227436B1 (en) 2014-12-05 2024-11-13 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
WO2016131769A2 (en) * 2015-02-16 2016-08-25 Lonza Ltd Antibodies
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10323094B2 (en) * 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
SG10202005268WA (en) * 2015-12-04 2020-07-29 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MY200034A (en) 2017-02-10 2023-12-05 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
BR112020001360A2 (pt) 2017-07-24 2020-08-11 Regeneron Pharmaceuticals, Inc. anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto.
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
AU2018360801A1 (en) 2017-11-01 2020-05-14 Celgene Corporation Process for producing a T cell composition
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
JP2021509009A (ja) 2017-11-30 2021-03-18 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
CN112203680A (zh) 2017-12-08 2021-01-08 朱诺治疗学股份有限公司 用于细胞疗法的表型标记和相关方法
KR102833956B1 (ko) 2017-12-08 2025-07-15 주노 쎄러퓨티크스 인코퍼레이티드 세포를 배양하기 위한 무혈청 배지 제형 및 이의 사용 방법
CN112004824B (zh) 2017-12-08 2024-09-13 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019316647A1 (en) 2018-08-09 2021-02-25 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
MA55811A (fr) 2019-05-01 2022-03-09 Editas Medicine Inc Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés
JP7754722B2 (ja) 2019-05-01 2025-10-15 ジュノー セラピューティクス インコーポレイテッド 改変されたｃｄ２４７遺伝子座からキメラ受容体を発現する細胞、関連ポリヌクレオチド、および方法
KR20220116522A (ko) 2019-12-20 2022-08-23 노파르티스 아게 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
CN115803824A (zh) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 鉴定与临床反应相关的特征的方法及其用途
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
JP7402381B2 (ja) 2020-11-04 2023-12-20 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
PE20231561A1 (es) 2020-12-23 2023-10-03 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2
EP4301755A1 (en) 2021-03-03 2024-01-10 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20250099579A1 (en) 2021-04-08 2025-03-27 Marengo Therapeutics, Inc. Multispecific molecules binding to tcr and uses thereof
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
JP2023546368A (ja) 2021-05-14 2023-11-02 ジェネンテック， インコーポレイテッド モスネツズマブおよびポラツズマブベドチンを用いたｃｄ２０陽性増殖性障害の処置のための方法
EP4469563A1 (en) 2022-01-28 2024-12-04 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
EP4479431A1 (en) 2022-02-18 2024-12-25 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
JP2025512342A (ja) 2022-04-13 2025-04-17 ジェネンテック， インコーポレイテッド 治療用タンパク質の医薬組成物および使用方法
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
CN117384299B (zh) * 2022-11-01 2024-04-30 邦恩泰(山东)生物医药科技集团股份有限公司 靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
CN116789849B (zh) * 2023-04-12 2024-03-08 南京紫珑生物科技有限公司 一种嵌合抗原受体及其应用
TW202525277A (zh) * 2023-08-10 2025-07-01 瑞典商阿斯特捷利康公司 蒽環黴素衍生物和綴合物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
ES2586850T3 (es) 1999-11-29 2016-10-19 The Trustees Of Columbia University In The City Of New York Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050226869A1 (en) 2001-10-19 2005-10-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005063299A2 (en) 2003-12-24 2005-07-14 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP5064037B2 (ja) * 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
WO2006039238A2 (en) * 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
AU2006204709A1 (en) 2005-01-12 2006-07-20 Medarex, Inc. IRTA-2 antibodies and their uses
EP2135881B1 (en) 2005-06-20 2011-09-07 Genentech, Inc. Antibodies binding to the tumour associated antigen TAT10772 for the diagnosis and treatment of tumor
WO2008109533A2 (en) 2007-03-02 2008-09-12 Medarex, Inc. Human antibodies that bind multiple irta family proteins, and uses thereof
ES2547552T3 (es) * 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
KR101667062B1 (ko) 2008-07-15 2016-10-17 제넨테크, 인크. 안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도
WO2010114940A1 (en) * 2009-04-01 2010-10-07 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
US8466260B2 (en) 2009-04-01 2013-06-18 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
TWI540136B (zh) * 2010-04-15 2016-07-01 梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use

Also Published As

Publication number Publication date
MX2015017331A (es) 2016-06-24
BR112015032224B1 (pt) 2024-01-02
PL3336106T3 (pl) 2020-11-16
LT3336106T (lt) 2020-08-10
DK3336106T3 (da) 2020-07-13
JP6684208B2 (ja) 2020-04-22
PT3336106T (pt) 2020-08-27
MX376663B (es) 2025-03-07
TW201508008A (zh) 2015-03-01
AU2014302617B2 (en) 2019-12-19
LT3736291T (lt) 2023-10-25
HK1222663A1 (zh) 2017-07-07
DK3013861T3 (da) 2018-01-22
ES2812243T3 (es) 2021-03-16
DK3736291T5 (da) 2024-08-26
FI3736291T3 (fi) 2023-09-25
LT3013861T (lt) 2018-02-12
WO2014210064A1 (en) 2014-12-31
SI3013861T1 (en) 2018-04-30
NZ715125A (en) 2021-08-27
ES2659229T3 (es) 2018-03-14
HRP20180352T1 (hr) 2018-04-06
MY176285A (en) 2020-07-27
AU2020201918A1 (en) 2020-04-02
CA2915480C (en) 2023-01-03
EP3013861A1 (en) 2016-05-04
CN116063515A (zh) 2023-05-05
DK3736291T3 (en) 2023-09-25
AU2014302617A1 (en) 2016-01-21
EP3013861B1 (en) 2017-11-29
IL269528A (en) 2019-11-28
US10435471B2 (en) 2019-10-08
RU2687132C2 (ru) 2019-05-07
HUE049446T2 (hu) 2020-09-28
PT3013861T (pt) 2018-02-21
EP3336106B1 (en) 2020-05-27
HRP20231323T1 (hr) 2024-02-16
ZA201509261B (en) 2019-03-27
PL3736291T3 (pl) 2024-02-05
EP3736291A1 (en) 2020-11-11
RS60418B1 (sr) 2020-07-31
MY191169A (en) 2022-06-03
SG10201804338PA (en) 2018-06-28
RU2019109452A (ru) 2019-05-29
PT3736291T (pt) 2023-11-08
RS64514B1 (sr) 2023-09-29
ZA201808451B (en) 2021-04-28
HRP20201111T1 (hr) 2020-10-30
IL243129B (en) 2019-09-26
SI3736291T1 (sl) 2023-12-29
BR112015032224A2 (pt) 2017-11-07
ES2962874T3 (es) 2024-03-21
CN105473618A (zh) 2016-04-06
SG11201510653YA (en) 2016-01-28
US11352431B2 (en) 2022-06-07
RS56878B1 (sr) 2018-04-30
HUE063910T2 (hu) 2024-02-28
JP2016528882A (ja) 2016-09-23
TWI725931B (zh) 2021-05-01
JP2020048559A (ja) 2020-04-02
US20150098900A1 (en) 2015-04-09
AR096687A1 (es) 2016-01-27
PL3013861T3 (pl) 2018-05-30
SI3336106T1 (sl) 2020-09-30
RU2016101965A (ru) 2017-07-28
HK1224313A1 (en) 2017-08-18
US20230096941A1 (en) 2023-03-30
HUE036581T2 (hu) 2018-07-30
EP3336106A1 (en) 2018-06-20
EP3736291B1 (en) 2023-08-16
CA2915480A1 (en) 2014-12-31
US20200190185A1 (en) 2020-06-18
NO2955475T3 (OSRAM) 2018-02-17
HK1257261A1 (en) 2019-10-18

Similar Documents

Publication Publication Date Title
US20230096941A1 (en) Anti-fcrh5 antibodies
KR101718200B1 (ko) 항-Ly6E 항체 및 면역접합체 및 사용 방법
JP2021104019A (ja) 抗ｃｄ３３抗体とイムノコンジュゲート
KR20150127199A (ko) 항-b7-h4 항체 및 면역접합체
KR20150003162A (ko) 항-lgr5 항체 및 면역접합체
KR20170003582A (ko) 항-gpc3 항체 및 면역접합체
KR20160111469A (ko) 항-steap1 항체 및 면역접합체를 사용하는 방법
KR20160055252A (ko) 항-lgr5 항체의 사용 방법
HK1257261B (en) Anti-fcrh5 antibodies
HK1224313B (en) Anti-fcrh5 antibodies
NZ715125B2 (en) Anti-fcrh5 antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190620

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200910

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201113

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200910

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I